EHAB

Enhabit Inc.
NYSEHEALTHCAREMEDICAL CARE FACILITIES

Key Statistics

Market Cap
$706.91M
P/E Ratio
EPS
$-0.07
Beta
0.96
52W High
$14.22
52W Low
$6.47
50-Day MA
$13.76
200-Day MA
$10.26
Dividend Yield
Profit Margin
-0.30%
Forward P/E
23.75
PEG Ratio

About Enhabit Inc.

Enhabit, Inc. provides home health and hospice services in the United States.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$1.06B
Gross Profit (TTM)$520.70M
EBITDA$80.30M
Operating Margin4.38%
Return on Equity-0.19%
Return on Assets3.08%
Revenue/Share (TTM)$20.89
Book Value$10.53
Price-to-Book1.28
Price-to-Sales (TTM)0.66
EV/Revenue1.067
EV/EBITDA21.05
Quarterly Earnings Growth (YoY)2.90%
Quarterly Revenue Growth (YoY)1.90%
Shares Outstanding$51.23M
Float$44.62M
% Insiders3.66%
% Institutions100.64%

Historical Volatility

HV 10-Day
1.46%
HV 20-Day
1.20%
HV 30-Day
5.16%
HV 60-Day
42.51%
HV Rank
0.0%

Volatility is currently contracting

Analyst Ratings

Consensus ($13.80 target)
6
Hold

Latest News

Enhabit Home Health & Hospice Announces New Chief Executive Officer

DALLAS--(BUSINESS WIRE)--Enhabit, Inc., a leading home health and hospice provider, today announced that Dale Clift has been appointed president and CEO, following the successful completion of the company's acquisition by Kinderhook Industries. Clift succeeds Barb Jacobsmeyer, former president and CEO of Enhabit, who previously announced her intention to step down upon the appointment of a successor. Clift brings decades of leadership experience in home health and hospice care. He previously se.

Business Wire5/18/2026Neutral
Fast-paced Momentum Stock Enhabit (EHAB) Is Still Trading at a Bargain

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Enhabit (EHAB) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Investment Research5/14/2026Positive
Enhabit (EHAB) Upgraded to Buy: Here's Why

Enhabit (EHAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research5/13/2026Positive

More HEALTHCARE Stocks

Data last updated: 5/19/2026